PACAP-38

N/A

Report date: 2022/01/22 15:45:52

Base Information

Drug NamePACAP-38
Drug Alias NamePituitary adenylate cyclase activating polypeptidePACAP-27PACAP-38PACAP 1-27PACAP 1-38 +[6] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionPituitary adenylate cyclase-activating polypeptide receptors antagonists
TargetsPituitary adenylate cyclase-activating polypeptide receptors
Therapy Area/IndicationsStrokeAsthmaCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTulane University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEndo International PlcTulane University
Active IndicationsN/A
Inactive IndicationsStrokeAsthmaCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A